Benzinga | Aug 31, 2021 06:02AM EDT

Stifel Initiates Coverage On Adagio Therapeutics with Buy Rating, Announces Price Target of $57

Stifel analyst Stephen Willey initiates coverage on Adagio Therapeutics (NASDAQ:ADGI) with a Buy rating and announces Price Target of $57.